Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

I Roots

Showing results (101-110 of 225) with videos related to

Pageof 23
Sort By:
Pharmacogenetics|January 14, 2000
The O-demethylation of the antidementia drug galanthamine is catalysed by cytochrome P450 2D6R Bachus, U Bickel, T Thomsen, et al.
Pharmacogenetics|June 1, 1996
NAT2*12A (803A-->G) codes for rapid arylamine n-acetylation in humansI Cascorbi, J Brockmöller, S Bauer, et al.
Biochemical Pharmacology|February 4, 1992
Correlation between trans-stilbene oxide-glutathione conjugation activity and the deletion mutation in the glutathione S-transferase class mu gene detected by polymerase chain reactionJ Brockmöller, D Gross, R Kerb, et al.
Antimicrobial Agents and Chemotherapy|September 1, 1996
Single-dose and steady-state pharmacokinetics of hypericin and pseudohypericinR Kerb, J Brockmöller, B Staffeldt, et al.
Der Nervenarzt|May 3, 2005
[The value of pharmacogenetic tests in antidepressive medication therapy]J Kirchheiner, J Sasse, I Roots, et al.
Lancet (London, England)|April 1, 1989
Immunosuppressive properties of cyclosporin metabolitesU Kunzendorf, J Brockmöller, F Jochimsen, et al.
Transplantation|September 1, 1989
Neurotoxicity caused by a high cyclosporine metabolite levelU Kunzendorf, J Brockmöller, F Jochimsen, et al.
Toxicology Letters|February 18, 1999
Polymorphisms in xenobiotic conjugation and disease predispositionJ Brockmöller, I Cascorbi, R Kerb, et al.
Clinical Chemistry and Laboratory Medicine|November 30, 2000
How to manage individualized drug therapy: application of pharmacogenetic knowledge of drug metabolism and transportC Meisel, I Roots, I Cascorbi, et al.
Pharmacology|September 6, 2000
Molecular genetics of cancer susceptibilityJ Brockmöller, I Cascorbi, S Henning, et al.
Pageof 23

Showing results (101-110 of 225) with videos related to

Sort By:
Pageof 23
Pharmacogenetics|January 14, 2000
The O-demethylation of the antidementia drug galanthamine is catalysed by cytochrome P450 2D6R Bachus, U Bickel, T Thomsen, et al.
Pharmacogenetics|June 1, 1996
NAT2*12A (803A-->G) codes for rapid arylamine n-acetylation in humansI Cascorbi, J Brockmöller, S Bauer, et al.
Biochemical Pharmacology|February 4, 1992
Correlation between trans-stilbene oxide-glutathione conjugation activity and the deletion mutation in the glutathione S-transferase class mu gene detected by polymerase chain reactionJ Brockmöller, D Gross, R Kerb, et al.
Antimicrobial Agents and Chemotherapy|September 1, 1996
Single-dose and steady-state pharmacokinetics of hypericin and pseudohypericinR Kerb, J Brockmöller, B Staffeldt, et al.
Der Nervenarzt|May 3, 2005
[The value of pharmacogenetic tests in antidepressive medication therapy]J Kirchheiner, J Sasse, I Roots, et al.
Lancet (London, England)|April 1, 1989
Immunosuppressive properties of cyclosporin metabolitesU Kunzendorf, J Brockmöller, F Jochimsen, et al.
Transplantation|September 1, 1989
Neurotoxicity caused by a high cyclosporine metabolite levelU Kunzendorf, J Brockmöller, F Jochimsen, et al.
Toxicology Letters|February 18, 1999
Polymorphisms in xenobiotic conjugation and disease predispositionJ Brockmöller, I Cascorbi, R Kerb, et al.
Clinical Chemistry and Laboratory Medicine|November 30, 2000
How to manage individualized drug therapy: application of pharmacogenetic knowledge of drug metabolism and transportC Meisel, I Roots, I Cascorbi, et al.
Pharmacology|September 6, 2000
Molecular genetics of cancer susceptibilityJ Brockmöller, I Cascorbi, S Henning, et al.
Pageof 23